Cargando…
Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326580/ https://www.ncbi.nlm.nih.gov/pubmed/33400775 http://dx.doi.org/10.1093/cid/ciaa1944 |
_version_ | 1783731857114791936 |
---|---|
author | Boikos, Constantina Fischer, Lauren O’Brien, Dan Vasey, Joe Sylvester, Gregg C Mansi, James A |
author_facet | Boikos, Constantina Fischer, Lauren O’Brien, Dan Vasey, Joe Sylvester, Gregg C Mansi, James A |
author_sort | Boikos, Constantina |
collection | PubMed |
description | BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018–2019 US season. METHODS: A dataset linking primary care electronic medical records with medical claims data was used to conduct a retrospective cohort study among individuals ≥ 4 years old vaccinated with ccIIV4 or eIIV4 during the 2018–2019 season. Adjusted odds ratios (ORs) were derived from a doubly robust inverse probability of treatment-weighted approach adjusting for age, sex, race, ethnicity, geographic region, vaccination week, and health status. rVE was estimated by (1 – OR) × 100 and presented with 95% confidence intervals (CI). RESULTS: Following the application of inclusion/exclusion criteria, the study cohort included 2 125 430 ccIIV4 and 8 000 903 eIIV4 recipients. Adjusted analyses demonstrated a greater reduction in influenza-related medical encounters with ccIIV4 versus eIIV4, with the following rVE: overall, 7.6% (95% CI, 6.5–8.6); age 4–17 years, 3.9% (95% CI, .9–7.0); 18–64 years, 6.5% (95% CI, 5.2–7.9); 18–49 years, 7.5% (95% CI, 5.7–9.3); 50–64 years, 5.6% (95% CI, 3.6–7.6); and ≥65 years, –2.2% (95% CI, –5.4 to .9). CONCLUSIONS: Adjusted analyses demonstrated statistically significantly greater reduction in influenza-related medical encounters in individuals vaccinated with ccIIV4 versus eIIV4 in the 2018–2019 US influenza season. These results support ccIIV4 as a potentially more effective public health measure against influenza than an egg-based equivalent. |
format | Online Article Text |
id | pubmed-8326580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83265802021-08-02 Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States Boikos, Constantina Fischer, Lauren O’Brien, Dan Vasey, Joe Sylvester, Gregg C Mansi, James A Clin Infect Dis Online Only Articles BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018–2019 US season. METHODS: A dataset linking primary care electronic medical records with medical claims data was used to conduct a retrospective cohort study among individuals ≥ 4 years old vaccinated with ccIIV4 or eIIV4 during the 2018–2019 season. Adjusted odds ratios (ORs) were derived from a doubly robust inverse probability of treatment-weighted approach adjusting for age, sex, race, ethnicity, geographic region, vaccination week, and health status. rVE was estimated by (1 – OR) × 100 and presented with 95% confidence intervals (CI). RESULTS: Following the application of inclusion/exclusion criteria, the study cohort included 2 125 430 ccIIV4 and 8 000 903 eIIV4 recipients. Adjusted analyses demonstrated a greater reduction in influenza-related medical encounters with ccIIV4 versus eIIV4, with the following rVE: overall, 7.6% (95% CI, 6.5–8.6); age 4–17 years, 3.9% (95% CI, .9–7.0); 18–64 years, 6.5% (95% CI, 5.2–7.9); 18–49 years, 7.5% (95% CI, 5.7–9.3); 50–64 years, 5.6% (95% CI, 3.6–7.6); and ≥65 years, –2.2% (95% CI, –5.4 to .9). CONCLUSIONS: Adjusted analyses demonstrated statistically significantly greater reduction in influenza-related medical encounters in individuals vaccinated with ccIIV4 versus eIIV4 in the 2018–2019 US influenza season. These results support ccIIV4 as a potentially more effective public health measure against influenza than an egg-based equivalent. Oxford University Press 2021-01-05 /pmc/articles/PMC8326580/ /pubmed/33400775 http://dx.doi.org/10.1093/cid/ciaa1944 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Online Only Articles Boikos, Constantina Fischer, Lauren O’Brien, Dan Vasey, Joe Sylvester, Gregg C Mansi, James A Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title | Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title_full | Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title_fullStr | Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title_full_unstemmed | Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title_short | Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States |
title_sort | relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018–2019 influenza season in the united states |
topic | Online Only Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326580/ https://www.ncbi.nlm.nih.gov/pubmed/33400775 http://dx.doi.org/10.1093/cid/ciaa1944 |
work_keys_str_mv | AT boikosconstantina relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates AT fischerlauren relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates AT obriendan relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates AT vaseyjoe relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates AT sylvestergreggc relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates AT mansijamesa relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates |